• Data
    • Overview
    • Clinical notes
    • Images
    • Mother-child
    • Oncology
    • Regulatory grade
    • Truveta Language Model
    • Truveta Live Link
    • Truveta Studio
  • Genomics
  • Solutions
    • Medical devices
    • Life science
    • Public health
    • Healthcare
  • Research
  • Resources
  • About
    • Blog
    • Members
    • Leadership
    • Events & webinars
    • News
    • Careers

Get started
Sign in
Close
Boston Scientific finds reduced infection risk with pressure monitoring ureteroscope

Boston Scientific finds reduced infection risk with pressure monitoring ureteroscope

by Truveta staff | Sep 30, 2025 | Featured research, Research

Infections remain one of the most concerning complications following ureteroscopy (URS), a common procedure to examine or treat kidney stones. Even though URS is considered a safe and routine procedure, postoperative infections can lead to serious outcomes, including...
Truveta experts: Adoption of MRSA testing for guiding treatment decisions

Truveta experts: Adoption of MRSA testing for guiding treatment decisions

by Truveta staff | Sep 25, 2025 | Research

Methicillin-resistant Staphylococcus aureus (MRSA) is one of the most serious infections, often leading healthcare providers to start powerful, broad-spectrum antibiotics like intravenous (IV) vancomycin. While vancomycin can be life-saving, unnecessary use...
Real-world analysis links Dexcom CGM use to reduced progression of chronic kidney disease

Real-world analysis links Dexcom CGM use to reduced progression of chronic kidney disease

by Truveta staff | Sep 16, 2025 | Research

Continuous glucose monitoring (CGM) is increasingly recognized not only for its role in diabetes management but also for its potential impact on broader health outcomes. A recent consensus statement highlighted the need for additional evidence on CGM use in people...
Truveta experts: Gestational diabetes screening in real-world practice

Truveta experts: Gestational diabetes screening in real-world practice

by Truveta staff | Sep 15, 2025 | Research

Gestational diabetes is one of the most common complications of pregnancy, affecting roughly 5–9% of pregnancies in the United States. When diagnosed and managed early, patients can avoid complications such as high birth weight, preterm delivery, or cesarean section....
Non-small cell lung cancer: Biomarkers, treatments, and outcomes in real-world data

Non-small cell lung cancer: Biomarkers, treatments, and outcomes in real-world data

by Truveta staff | Sep 12, 2025 | Research

Non–small cell lung cancer (NSCLC) accounts for about 85% of lung cancer cases and remains the leading cause of cancer death worldwide. While major advances in targeted therapies and immunotherapies have transformed care, gaps persist in biomarker testing, treatment...
Impact of the CVS GLP-1 formulary change: Trends in switching

Impact of the CVS GLP-1 formulary change: Trends in switching

by Truveta Research | Sep 5, 2025 | Research, Research Insights

In July 2025, following the CVS formulary change, 9.6% of patients on AOM tirzepatide switched to a different drug. This was more than a 16-fold increase compared with the average earlier in the year. Among AOM tirzepatide users who switched to a different GLP-1...
« Older Entries
Next Entries »

Share this


Recent posts

  • Real-world evidence on heart failure from GLP-1 and advanced CKD populations
  • Early uptake of oral semaglutide for obesity (Wegovy pill) following FDA approval
  • Use of GLP-1 RAs following label expansion for patients with CVD and overweight or obesity

Follow Truveta


Sign up for our newsletter

Ready to accelerate your research with representative, complete, and timely real-world data?

Truveta Data

Truveta Genome Project

Research

Resources

Blog

News

Careers

Privacy notice

Contact us

© Truveta 2026

Our website uses cookies to ensure you have the best experience.